Tower Research Capital (TRC)’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-7,398
| Closed | -$43K | – | 6665 |
|
|
2022
Q4 | $43K | Buy |
7,398
+5,351
| +261% | +$28.1K | ﹤0.01% | 2480 |
|
|
2022
Q3 | $14K | Sell |
2,047
-27,165
| -93% | -$165K | ﹤0.01% | 4246 |
|
|
2022
Q2 | $123K | Buy |
29,212
+4,205
| +17% | +$16.6K | ﹤0.01% | 2131 |
|
|
2022
Q1 | $84K | Buy |
25,007
+11,316
| +83% | +$35.9K | ﹤0.01% | 2348 |
|
|
2021
Q4 | $44K | Buy |
13,691
+10,366
| +312% | +$34.5K | ﹤0.01% | 2871 |
|
|
2021
Q3 | $11K | Sell |
3,325
-2,975
| -47% | -$10.4K | ﹤0.01% | 4281 |
|
|
2021
Q2 | $27K | Sell |
6,300
-4,391
| -41% | -$18.6K | ﹤0.01% | 3621 |
|
|
2021
Q1 | $53K | Buy |
10,691
+5,224
| +96% | +$42.2K | ﹤0.01% | 3080 |
|
|
2020
Q4 | $69K | Sell |
5,467
-24,751
| -82% | -$282K | ﹤0.01% | 2744 |
|
|
2020
Q3 | $297K | Buy |
30,218
+25,104
| +491% | +$247K | ﹤0.01% | 2201 |
|
|
2020
Q2 | $51K | Buy |
+5,114
| New | +$49K | ﹤0.01% | 3037 |
|
|
2020
Q1 | – | Sell |
-409
| Closed | -$4K | – | 4190 |
|
|
2019
Q4 | $4K | Sell |
409
-272
| -40% | -$1.93K | ﹤0.01% | 2842 |
|
|
2019
Q3 | $4K | Buy |
+681
| New | +$7.23K | ﹤0.01% | 3487 |
|
|
2019
Q2 | – | Sell |
-288
| Closed | -$3K | – | 4509 |
|
|
2019
Q1 | $3K | Sell |
288
-635
| -69% | -$9.36K | ﹤0.01% | 3340 |
|
|
2018
Q4 | $12K | Buy |
+923
| New | +$12.7K | ﹤0.01% | 2350 |
|
|
2018
Q3 | – | Sell |
-4,537
| Closed | -$76K | – | 4393 |
|
|
2018
Q2 | $76K | Buy |
+4,537
| New | +$88.1K | ﹤0.01% | 1610 |
|
|
2017
Q4 | – | Sell |
-3,456
| Closed | -$51K | – | 4192 |
|
|
2017
Q3 | $51K | Buy |
+3,456
| New | +$50.2K | ﹤0.01% | 1965 |
|
|
2017
Q1 | – | Sell |
-3,998
| Closed | -$41K | – | 4147 |
|
|
2016
Q4 | $41K | Buy |
+3,998
| New | +$36.5K | ﹤0.01% | 1562 |
|
|
2016
Q1 | – | Sell |
-456
| Closed | -$9K | – | 5173 |
|
|
2015
Q4 | $9K | Buy |
+456
| New | +$9.91K | ﹤0.01% | 2318 |
|
|
2014
Q3 | – | Sell |
-3,169
| Closed | -$32K | – | 5020 |
|
|
2014
Q2 | $32K | Buy |
3,169
+1,503
| +90% | +$14.5K | ﹤0.01% | 1567 |
|
|
2014
Q1 | $22K | Buy |
+1,666
| New | +$23.5K | ﹤0.01% | 1800 |
|
Tower Research Capital (TRC)'s CNCE Position: Q1 2023 in Review
Tower Research Capital (TRC) sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 7,398 shares — an estimated $43K sold.
Tower Research Capital (TRC) first reported a position in CNCE in Q1 2014 and held it in 21 quarters. The position peaked at $297K in Q3 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Tower Research Capital (TRC) reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 7,398 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $43K.
- Tower Research Capital (TRC) first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 21 quarters.
- Tower Research Capital (TRC)'s Concert Pharmaceuticals, Inc. position peaked at $297K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.